Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls
Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls
Sponsor: Regional Hospital Holstebro
This PHASE1 trial investigates Hypertension and is currently completed. Regional Hospital Holstebro leads this study, which shows 5 recorded versions since 2026 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Study Description(click to expand)The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:
1. renal hemodynamics (renal plasma flow and glomerular filtration rate)
2. renal sodium excretion
3. lithium clearance and fractional lithium excretion
4. plasma levels of vasoactive hormones
5. blood pressure and heart rate
The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:
1. renal hemodynamics (renal plasma flow and glomerular filtration rate) 2. renal sodium excretion 3. lithium clearance and fractional lithium excretion 4. plasma levels of vasoactive hormones 5. blood pressure and heart rate
Status Flow
Change History
5 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Regional Hospital Holstebro
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.